Efficacy of high-dose therapy and autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in adults 60 years of age and older

Bone Marrow Transplantation
Ajay K GopalOliver W Press

Abstract

High-dose therapy (HDT) with autologous stem cell transplantation (ASCT) is the optimal treatment for patients with relapsed aggressive non-Hodgkin's lymphoma (NHL). HDT, however, is often reserved for relatively younger patients due to limited data in older adults. We treated 53 patients aged 60 years and older (median age 62 years, range 60.3-67.7 years) with HDT and ASCT for NHL at our centers. Forty-four patients (83%) had aggressive histology, 75% had chemosensitive disease and all had failed anthracycline therapy. Conditioning regimens included busulfan, melphalan, and thiotepa (45%); cyclophosphamide (CY), etoposide (VP-16), and total body irradiation (TBI) (30%); CY and TBI (15%); and other regimens (10%). Estimated 4-year overall survival (OS), progression-free survival, and treatment-related mortality (TRM) were 33%, 24% and 22%, respectively. A multivariable analysis demonstrated that patients with chemosensitive disease (P = 0.03) and < or =3 prior regimens (P = 0.03) had superior survival. Four-year OS in patients with chemosensitive disease was 39% vs 15% in patients with chemoresistant disease. Reduced TRM was associated with the CY, VP-16 and TBI regimen (P = 0.02). HDT therapy with ASCT may result in prolonged ...Continue Reading

References

Jun 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S GulatiE Hanninen
Apr 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F B PetersenR Storb
Sep 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S I BearmanE D Thomas
Jul 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M A RodriguezJ E Romaguera
Aug 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W H WilsonB D Cheson
May 1, 1993·Current Problems in Cancer·A Byrne, D N Carney
Apr 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C B MillerR J Jones
Jan 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C R Kusnierz-GlazG D Long
Feb 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P J BiermanJ O Armitage
Jun 17, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H GómezC Vallejos

❮ Previous
Next ❯

Citations

Jun 9, 2005·Hematology/oncology Clinics of North America·Richard Carvajal, Paul Meyers
Oct 17, 2006·Bone Marrow Transplantation·E Jantunen
Mar 10, 2010·Drugs & Aging·Paolo F CaimiHillard M Lazarus
May 7, 2010·Leukemia & Lymphoma·Mathias Witzens-Harig, Peter Dreger
Apr 3, 2008·Seminars in Hematology·Michelle M Zhang, Ajay K Gopal
Nov 15, 2006·Clinical Transplantation·Matt KalaycioBrian Bolwell
Oct 10, 2006·Seminars in Hematology·Auayporn Nademanee, Stephen J Forman
Jun 30, 2015·British Journal of Haematology·Satyen H GohilKarl S Peggs
Feb 18, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Ajay K GopalOliver W Press
Jul 24, 2015·Current Oncology Reports·Oscar B LahoudParastoo Bahrami Dahi
Feb 5, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Dai ChiharaJunji Suzumiya
Dec 2, 2008·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Hillard M LazarusUNKNOWN Center For International Blood & Marrow Transplant Research (CIBMTR)
Mar 27, 2007·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Rachel E LernerLinda J Burns
Jun 19, 2003·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Jacob D BitranJosie Rowen
Jun 18, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Solomon A GrafMohamed L Sorror
Feb 22, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ajay K GopalOliver W Press
May 10, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Catherine Thieblemont, Bertrand Coiffier
Jan 19, 2011·Bone Marrow Transplantation·N PuigM Crump
Jun 14, 2018·The Oncologist·Haige YeMichael L Wang
Mar 30, 2019·Experimental Hematology & Oncology·Mattias CarlstenBjörn Engelbrekt Wahlin
Feb 15, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C HosingI Khouri

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.